Optimizing Treatment of Patients with Co-Existing Cardiorespiratory Pathology by Administration of Anti-Inflammatory Roflumilast and Cardioprotective Agent Quercetin

P. R. Herych, R. I. Yatsyshyn

Abstract


The article discusses the research findings on the effectiveness and safety of combination treatment with roflumilast and quercetin in aggravated chronic obstructive pulmonary disease (COPD) along with a co-occurring comorbid ischemic heart disease (IHD). Clinical evidence highlights the effect of combination of roflumilast and quercetin as a part of the basic treatment of COPD and conventional treatment of IHD on clinical symptomatology, C-reactive protein levels, and α2-macroglobulin in plasma. It was found that a complex therapy leads to a substantial improvement of patients’ clinical condition owing to reduced systemic inflammatory activation and improved immune defense, which decreases incidence of cardiovascular complications.

Keywords


chronic obstructive pulmonary disease; ischemic heart disease; inflammatory biomarkers

Full Text:

PDF

References


Global initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. Available from http.www.goldcopd.com.

Feshchenko Yu.I. Questions on chronic obstructive pulmonary disease. Ukr.pulmonoloh.zhurn. 2010; 1: 6.

Mostovoy Yu.M. COPD: invitation to participate in discussion. Novosti meditsiny i farmatsii. 2008; 19(261): 6-8.

Karoli N.A. Orlova E. Ye., Markova A.V., Rebrov A.P. Ter. arkhiv. 2008; 3: 20-23.

Gurkendall S. M. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada Cardiovascular disease in COPD patients. S. M. Gurkendall, С. Demise, J.K. Jones et al. Ann. Epidemiol. 2006; 16: 63-70.

Huiart L. Cardiovascular morbidity and mortality in COPD. L. Huiart, Р. Ernst, S. Suissa. Chest. 2005; 128: 2640-2646.

Chicherina E. N., Milyutina O.V. Systemic inflammation and atherosclerosis of the common carotid arteries in patients with chronic obstructive pulmonary disease. Klin. meditsina. 2009; 2: 18-20.

Pertseva T.O., Konopkina L.I. The role of the markers of systemic inflammation in development of immune response to an infection/colonization in patients with COPD. Ukr. pulmonoloh. Zhurnal. 2007; 1: 22-25.

Tatenkulova S.N., Mareyev V.Yu., Zykov K.A., Belenkov Yu. N. The role of humoral inflammatory factors in the pathogenesis of ischemic heart disease. Kardiologiya. 2009; 1: 4-9.

Order of the Ministry of Health Care of Ukraine No 555 dated June 27, 2013 “On approval and implementation of medical-and-technical documents on standardization of medical care in chronic obstructive pulmonary disease”. Kyiv. 2013.

Order of the Ministry of Health Care of Ukraine No 436 dated July 03, 2006 “On approval and implementation of protocols for provision of medical services in cardiology”. 2007; 146.




Copyright (c) 2017 P. R. Herych, R. I. Yatsyshyn

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


IFNMU Logo

Free counters!